PURPOSE: To  explore, in a dose-escalation study, the feasibility of hyperbaric @entity26 (HBO) treatments immediately before intensity modulated radiation therapy in conjunction with @entity900 chemotherapy for @entity213 ( @entity213 ). METHODS AND MATERIALS: Eligible @entity1 presented with @entity213 (stage III-IV [M0]), life expectancy >6  months, and Karnofsky performance status >= 70. Enrollees received intensity modulated radiation therapy, 70  Gy in 35 fractions over 7  weeks with weekly @entity900 . @entity1 received HBO-100% @entity26 , 2.4  atmospheres absolute (ATA) for 30 minutes-twice per week initially. Subsequent @entity1 were escalated to 3 and then 5 times per week. Intensity modulated radiation  therapy began within 15  minutes after HBO. @entity1 were followed for  2  years after RT with quality-of-life questionnaires (Performance Status Scale-Head and @entity135 and the Functional Assessment of @entity5 Therapy-Head and @entity135 ) and for 5+  years for local recurrence, distant metastases, disease-specific survival, and overall survival. RESULTS: Twelve subjects enrolled from 3 centers. Two withdrew during radiation therapy and 1 within 14  weeks after radiation therapy. The remaining 9 had primary @entity66 and were stage IVA (7) or IVB (2). No dose-limiting @entity137 were observed with daily HBO. Two @entity1 (22%) required pressure equalization tubes. The average time between HBO and radiation therapy was 8.5  minutes, with 2 of 231 administrations delivered beyond 15  minutes (0.5%). Per-protocol analysis showed a clinical complete response in 7 and a pathologic complete response without @entity5 in salvage neck dissections in 2. With minimum follow-up of 61  months, per-protocol 5-year overall survival was 100%, local recurrence 0%, and distant metastases 11%. @entity1 -reported outcomes for quality of life (Functional Assessment of @entity5 Therapy-Head and @entity135 ) were comparable to published results for chemoradiotherapy without HBO. CONCLUSIONS: While acknowledging the study's small size and early attrition of 3 @entity1 , our in-depth review of the acquired data indicates the feasibility of combining HBO with chemoradiation.

Hyperbaric XXXX as Radiation Sensitizer for Locally Advanced Squamous Cell Carcinoma of the Oropharynx: A Phase 1 Dose-Escalation Study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Patient'] @entity135 :: ('MESH:D006258', 'Disease') :: ['Neck Cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity66 :: ('MESH:D004194', 'Disease') :: ['oropharyngeal disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Cancer'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatinum'] @entity213 :: ('MESH:C535575', 'Disease') :: ['squamous cell carcinoma of the head and neck', 'SCCHN']
@entity26 :: (MESH:D010100,Chemical) :: ['Oxygen']
